Drug Development Consulting Holding ApS — Credit Rating and Financial Key Figures
CVR number: 42285722
Smedeland 36, Smedeland 2600 Glostrup
Income statement (kDKK)
2021 | 2022 | 2023 | |
|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 |
| Net sales | |||
| Gross profit | 40.00 | -58.30 | -53.33 |
| EBIT | 40.00 | -58.30 | -53.33 |
| Other financial income | 17.00 | 52.00 | |
| Net income from associates (fin.) | -15 752.00 | -11 831.00 | -9 381.00 |
| Pre-tax profit | -15 712.00 | -11 872.30 | -9 382.33 |
| Income taxes | -2.00 | 6.00 | |
| Net earnings | -15 712.00 | -11 874.30 | -9 376.33 |
Assets (kDKK)
2021 | 2022 | 2023 | |
|---|---|---|---|
| Intangible assets total | |||
| Tangible assets total | |||
| Holdings in group member companies | 70 809.00 | 71 831.00 | 70 212.00 |
| Investments total | 70 809.00 | 71 831.00 | 70 212.00 |
| Long term receivables total | |||
| Inventories total | |||
| Current deferred tax assets | 7.00 | 6.00 | |
| Short term receivables total | 7.00 | 6.00 | |
| Cash and bank deposits | 183.00 | 264.00 | |
| Cash and cash equivalents | 183.00 | 264.00 | |
| Balance sheet total (assets) | 70 809.00 | 72 021.00 | 70 482.00 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | |
|---|---|---|---|
| Share capital | 200.00 | 228.00 | 245.00 |
| Share premium account | 86 321.00 | 99 293.00 | 107 163.00 |
| Retained earnings | -15 659.00 | -27 571.30 | |
| Profit of the financial year | -15 712.00 | -11 874.30 | -9 376.33 |
| Shareholders equity total | 70 809.00 | 71 987.70 | 70 460.37 |
| Provisions | 0.30 | -0.37 | |
| Non-current liabilities total | |||
| Other non-interest bearing current liabilities | 33.00 | 22.00 | |
| Current liabilities total | 33.00 | 22.00 | |
| Balance sheet total (liabilities) | 70 809.00 | 72 021.00 | 70 482.00 |
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.